K. Kerr discusses the study of the whole-exome sequencing in NSCLC tumours. The findings demonstrate spatial and temporal heterogeneity of driver mutations and copy number events. The study is an attempt to address an unmet need to elicit the implications of intratumour heterogeneity for biomarker validation, therapeutic response and patients survival.